Pygopus-2 promotes invasion and metastasis of hepatic carcinoma cell by decreasing E-cadherin expression

被引:22
作者
Zhang, Sheng [1 ]
Li, Jie [1 ]
Liu, Pingguo [1 ]
Xu, Jianfeng [1 ]
Zhao, Wenxiu [1 ]
Xie, Chengrong [1 ]
Yin, Zhenyu [1 ]
Wang, Xiaomin [1 ]
机构
[1] Xiamen Univ, ZhongShan Hosp, Fujian Prov Key Lab Chron Liver Dis & Hepatocellu, Dept Hepatobiliary Surg, Xiamen, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
pygopus-2; E-cadherin; hepatic carcinoma; invasion; metastasis; STEM-CELLS; WNT; CANCER; CATENIN; PATHWAY; TARGET; MICE; ZEB;
D O I
10.18632/oncotarget.3570
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pygopus-2 over-expression has been reported in several malignancies, such as ovarian, breast, lung and liver cancers. Here we demonstrated that down-regulation of Pygopus-2 by shRNA inhibited hepatic carcinoma cell invasion in vitro and metastasis in xenograft tumor models, which were promoted when Pygopus-2 was overexpressed. Pygopus-2 increased hepatic carcinoma cell invasion and metastasis, by decreasing E-cadherin. Pygopus-2 could bind to the E-cadherin promoter, increasing its methylation, and also indirectly decreased zeb2 expression. In turn these effects caused down-regulation of E-cadherin, potentiating invasion and metastasis. We suggest that targeting Pygopus-2 may potentially inhibit metastasis of hepatic carcinoma.
引用
收藏
页码:11074 / 11086
页数:13
相关论文
共 45 条
[1]  
Andrews PGP, 2007, INT J ONCOL, V30, P357
[2]  
[Anonymous], 2020, CA Cancer J Clin, DOI DOI 10.3322/CAAC.21590
[3]   Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer [J].
Bae, Gab-Yong ;
Choi, So-Jung ;
Lee, Ji-Seon ;
Jo, Jisuk ;
Lee, Jinseon ;
Kim, Jhingook ;
Cha, Hyuk-Jin .
ONCOTARGET, 2013, 4 (12) :2512-2522
[4]  
Belenkaya TY, 2002, DEVELOPMENT, V129, P4089
[5]   Primary liver cancer:: Worldwide incidence and trends [J].
Bosch, FX ;
Ribes, J ;
Díaz, M ;
Cléries, R .
GASTROENTEROLOGY, 2004, 127 (05) :S5-S16
[6]   Repression of E-cadherin by the polycomb group protein EZH2 in cancer [J].
Cao, Q. ;
Yu, J. ;
Dhanasekaran, S. M. ;
Kim, J. H. ;
Mani, R-S ;
Tomlins, S. A. ;
Mehra, R. ;
Laxman, B. ;
Cao, X. ;
Yu, J. ;
Kleer, C. G. ;
Varambally, S. ;
Chinnaiyan, A. M. .
ONCOGENE, 2008, 27 (58) :7274-7284
[7]   Pygo2 Associates with MLL2 Histone Methyltransferase and GCN5 Histone Acetyltransferase Complexes To Augment Wnt Target Gene Expression and Breast Cancer Stem-Like Cell Expansion [J].
Chen, Jiakun ;
Luo, Qicong ;
Yuan, Yuanyang ;
Huang, Xiaoli ;
Cai, Wangyu ;
Li, Chao ;
Wei, Tongzhen ;
Zhang, Ludi ;
Yang, Meng ;
Liu, Qingfeng ;
Ye, Guodong ;
Dai, Xing ;
Li, Boan .
MOLECULAR AND CELLULAR BIOLOGY, 2010, 30 (24) :5621-5635
[8]   Nuclear E-cadherin immunoexpression - From biology to potential applications in diagnostic pathology [J].
Chetty, Runjan ;
Serra, Stefano .
ADVANCES IN ANATOMIC PATHOLOGY, 2008, 15 (04) :234-240
[9]   Prognostic factors for hepatocellular carcinoma recurrence [J].
Colecchia, Antonio ;
Schiumerini, Ramona ;
Cucchetti, Alessandro ;
Cescon, Matteo ;
Taddia, Martina ;
Marasco, Giovanni ;
Festi, Davide .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (20) :5935-5950
[10]   The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma [J].
Dahmani, Rajae ;
Just, Pierre-Alexandre ;
Perret, Christine .
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2011, 35 (11) :709-713